Press Release Archive

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that China’s Ministry of Commerce has approved the company’s pending acquisition of Wyeth. The Ministry’s decision includes Pfizer’s commitment to divest certain animal health assets in China. “We are pleased to have achieved another significant milestone with the Ministry’s approval of the pending transaction,” said Jeff Kindler,

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that its agreement with Eisai to provide Aricept to patients suffering from Alzheimer’s disease will continue without interruption. Under this redefined alliance, which resolves a previously disclosed dispute, Pfizer and Eisai will continue to co-promote Aricept in the U.S., Japan and key markets in Europe, and Pfizer will continue to have an exclusive license to sell Aricept in the

(BUSINESS WIRE)--In a new online survey, eighty-five percent of people who experience diabetic nerve pain said that their pain was one of the top three most bothersome complications of their diabetes. Despite the fact that people with diabetic nerve pain recognize the condition’s impact on their lives and eighty-four percent of those surveyed said they have discussed the condition with a healthcare provider, just slightly less than half

(BUSINESS WIRE)--Pfizer Inc has been named among the 2009 Working Mother 100 Best Companies for its steadfast commitment to family-friendly benefits. Pfizer and the other winning companies are pioneering programs that support families, with 100 percent offering flextime, on-site lactation and telecommuting; and 98 percent offering job-sharing and wellness programs—numbers that dwarf those seen nationwide. In addition, financial programs

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Wyeth (NYSE: WYE) today announced that they have entered into an agreement with Boehringer Ingelheim to divest certain animal health assets in connection with the regulatory approval process associated with Pfizer’s pending acquisition of Wyeth. Under the terms of the agreement, Boehringer Ingelheim will acquire products, research and manufacturing facilities, located in Fort Dodge,

(BUSINESS WIRE)--Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer,1 updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET),2 and early-stage research of investigational agents PF-023410663 and figitumumab (CP-751,871)4 in patients with non-small cell

(BUSINESS WIRE)--Pfizer Inc today announced that it has finalized a previously reported agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005. The final agreement also resolves other DOJ investigations involving alleged past off-label promotional practices concerning Zyvox, Geodon

(BUSINESS WIRE)--For patients with established heart disease who were treated with a statin, 18 novel biomarkers including C-reactive protein (CRP) did not predict future cardiovascular events such as heart attack and stroke, according to results of an analysis presented today at the 2009 European Society of Cardiology Congress in Barcelona, Spain. By contrast, traditional lipid risk factors were RCELONA, Spain--strong predictors of cardiovascular

(BUSINESS WIRE)--Pfizer Inc today announced that it has earned a score of 100 — the highest possible — in the 2010 Corporate Equality Index, which evaluates U.S.-based businesses on their treatment of lesbian, gay, bisexual and transgender (LGBT) employees, investors and consumers. The Corporate Equality Index — published annually by the Human Rights Campaign Foundation (HRCF), the largest LGBT advocacy organization